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Abstract
Background: Although prostatitis syndrome (PS) and irritable bowel syndrome (IBS) are common disorders, information on
the prevalence of IBS in infertile patients with PS is relatively scanty. Therefore, this study was undertaken to estimate the
frequency of PS and IBS and to evaluate the prevalence of the various diagnostic categories of prostatitis.
Methodology/Principal Findings: This study enrolled 152 patients with PS, diagnosed by the NIH-Chronic Prostatitis
Symptom Index (NIH-CPSI) in an andrological setting, and 204 patients with IBS, diagnosed according to the Rome III
diagnostic criteria in a gastroenterological setting. The patients with PS were asked to fulfill the Rome III questionnaire for
IBS, whereas patients with IBS were asked to complete the NIH-CPSI. The simultaneous presence of PS and IBS was observed
in 30.2% and 31.8% of the patients screened by andrologists and gastroenterologists, respectively. Altogether, 111 patients
had PS plus IBS (31.2%). They had a total NIH-CPSI and pain subscale scores significantly higher than patients with PS alone.
Gastrointestinal symptoms in patients with PS plus IBS were similar to those reported by patients with IBS alone and
significantly greater in patients with PS alone. Patients with PS plus IBS had a significantly higher frequency of chronic
bacterial prostatitis (category II) and lower of non-inflammatory prostatitis (category IIIB), compared to patients with PS
alone. The frequency of inflammatory prostatitis (category IIIA) resulted similar.
Conclusions/Significance: Prostatitis syndromes and IBS are frequently associated in patients with PS- or IBS-related
symptoms. These patients have an increased prevalence of chronic bacterial and non-inflammatory prostatitis.
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Introduction
Prostatitis syndrome (PS) and irritable bowel syndrome (IBS)
share some peculiar features: they are functional, somatoform
disorders; have a high worldwide prevalence; symptoms have a
substantially negative impact on the patients’ quality of life; are
defined on the basis of the clinical presentation rather than clear
diagnostic markers or findings.
PS, a common syndrome affecting relatively young men, is the
most frequent subtype of prostatitis encountered by family
physicians, internists, and urologists. It has a prevalence of 11–
16% [1,2], an unclear etiology, and a significant negative impact
on the quality of life, comparable to active Crohn’s disease or a
recent myocardial infarction [3]. The diagnosis of PS is based on
the presence of chronic and variable symptoms mix which includes
genitourinary pain (perineum, pelvis, suprapubic area and/or the
external genitalia), the hallmark symptom of this syndrome. It
causes also a variable degree of voiding and/or ejaculatory
disturbance [4,5]. To facilitate history taking and to establish a
more uniform standard, the National Institutes of Health (NIH),
USA, collaborative panel proposed the NIH-Chronic Prostatitic
Symptom Index (NIH-CPSI), considered the first validated tool for
assessing symptom severity in PS, useful for quantifying signs and
symptoms and their impact on a patient’s quality of life [5,6]. In
addition, among all the laboratory test designed to localize
bacteria and/or leucocytes in segmented urinary tract specimens,
the gold standard is the four glasses test proposed by Meares and
Stamey [7]. It consists of obtaining the following specimens for
microscopy and microbiological culture: the first voided 5–10 ml
urine (VB1), midstream urine (VB2), pure prostatic secretion
expressed by prostatic massage (EPS) and the first voided 5–10 ml
urine after prostatic massage (VB3). The presence of microorgan-
ism(s) and/or leukocytes or no microorganisms and leukocytes in
EPS and/or VB3 allows to diagnose chronic bacterial prostatitis
(category II), inflammatory prostatitis (category IIIA) and non-
inflammatory prostatitis (category IIIB), respectively [8]. Since
bacterial prostatitis (acute or chronic) accounts for a low
percentage (5–10%), the most significant proportion of the
urologic population studied has chronic non-bacterial prostatitis
(60–65%) or prostatodynia (30%) [9].
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population worldwide, varying from 6.2% in The Netherlands to
12% in Italy and the UK [10,11]. Its incidence is 1–2% per year
[12]. IBS is defined by the Rome III criteria as an abdominal pain
or discomfort, often associated with defecation (which relieves the
pain), and at least two of the following features: altered frequency,
consistency, and/or passage of stools; feelings of abdominal
distension or bloating [12]. The symptoms have to be present
for a minimum of three months, and evidence for an organic
underlying cause must be excluded to establish the diagnosis [10–
13]. The etiopathogenesis, which is not fully understood, may be
multifactorial, as it is the pathophysiology, which is attributed to
alterations of the gastrointestinal motility, visceral hypersensitivity,
dysfunction of the brain-gut axis (abnormal interactions between
exacerbating factors and gastrointestinal function, as well as on
interaction between different parts of our nervous system and the
gastrointestinal tract), neuroimmune dysregulation, post-infectious
inflammation or certain psychosocial factors [14–16]. The Rome
III criteria, in conjunction with a careful anamnesis (medical,
familiar, and medication assumption) and thorough physical
examination, should be applied as part of the stepwise,
symptom-based approach to diagnose IBS.
A large number of patients with IBS is additionally afflicted by
other somatic intestinal and/or extraintestinal co-morbidities
[17,18]. An elevated percentage of patients with IBS has other
somatoform pain and psychiatric syndromes [19–22]. It is not
clear whether the increase in frequency of extra-intestinal
symptoms reflects a systemic underlying disease with different
manifestations in various organs or it is expression of a
psychosomatic disorder [23]. The best documented non-gastroin-
testinal, non-psychiatric disorders affecting IBS patients include:
temporo-mandibular joint disorder (64%), chronic fatigue syn-
drome (51%), chronic pelvic pain (50%), and fibromyalgia (49%)
[24].
Little is known about the possible presence of co-morbidities in
patients with PS. Some of the most basic information are not
available. For example, population-based, age-specific prevalence
and incidence rates for many major urologic diseases are not
known. Overlap between symptoms of different urologic condi-
tions [eg, interstitial cystitis and chronic pelvic pain syndrome
(CPPS), or CPPS and prostatitis] has not been adequately assessed.
Only limited population-based information is presently accessible
on the epidemiology of major urologic diseases. A smaller
proportion is reported, receives an accurate diagnosis, and is
recorded as a case, constituting only the ‘‘tip of the iceberg’’. This
epidemiological metaphor appears useful to understand urologic
symptoms in the general population.
Recently, the research has focused on the co-morbidity between
urological and non-urological unexplained clinical conditions,
revealing a strong overlap up to 79% between chronic prostatitis
(CP)/CPPS) and symptoms of IBS [25]. Furthermore, studies
conducted in women showed allergies, urinary incontinence,
sinusitis, endometriosis, pelvic inflammatory disease (PID), pelvic
adhesions most frequently associated with chronic pelvic pain
[26,27]. In contrast, the few data available in men with CP/CPPS
showed allergies, sinusitis, erectile dysfunction and IBS among the
most common co-morbidities [28]. Li and co-workers found that
the incidence of altered bowel habits was present in 31.4% of 379
men with chronic prostatitis [29].
Thus, this study was undertaken to evaluate the simultaneous
presence of PS and IBS in two distinct groups of patients
consulting an Andrology and a Gastroenterology clinical Divi-
sions. To accomplish this, we enrolled 152 patients with PS,
diagnosed by the NIH-Chronic Prostatitis Symptom Index (NIH-
CPSI), and 204 patients with IBS, diagnosed according to the
Rome III diagnostic criteria. The patients with PS were asked to
fulfill the Rome III questionnaire for IBS, whereas patients with
IBS were asked to complete the NIH-CPSI. In patients with PS
plus IBS, we then evaluated the prevalence of the various
diagnostic categories of prostatitis.
Results
Of the 152 infertile patients with prostatitis diagnosed by
andrologists, 46 (30.3%) had also IBS, whereas 65 (31.9%) out of
204 patients with IBS diagnosed by gastroenterologists had also
prostatitis, with a median NIH-CPSI score of 14 (range 11–21),
and couple’s infertility. All patients with PS and IBS (n=111) and
the matched-group of the 106 patients with PS alone were
categorized to diagnose the various categories of prostatitis and
underwent semen analysis.
The mean age was similar in the patients with PS plus IBS, PS
alone and in the group of fertile normal men (controls), whereas
the time since diagnosis was higher, though not statistically
significant, in patients with PS plus IBS (Table 1). Patients with PS
plus IBS has a significantly higher total or pain subscale NIH-
CPSI score compared with all the others groups of patients and
controls (Table 1). The prevalence of various gastrointestinal
symptoms was significantly higher in both groups of patients with
PS plus IBS and IBS alone (Table 1). The severity score of
abdominal bowel habits was similar in patients with PS plus IBS
and IBS alone, but significantly higher than that found patients
with PS alone or in the controls (Table 2).
Thesubtypingofpatientsbyusingthe fourglasstest,performed in
all patients with PS plus IBS (n=111) and in patients with PS alone
(n=106), allowed to identify the presence of 3 categories of
prostatitis.The frequencyofchronic bacterial prostatitis (category II)
resulted significantly higher in patients with PS plus IBS compared
to those with PS alone (p,0.01), whereas the frequency of non-
inflammatory prostatitis (category IIIB) was significantly lower
(p,0.01).Finally,thefrequencyofinflammatoryprostatitis(category
IIIA) was similar in the 2 groups (Table 3).
Discussion
It is worth of mention that while IBS diagnosis is based on an
international consensus, such a consensus is missing for prostatitis
syndromes. The second argument to keep in mind it that, in
contrast to other syndromes that are usually based on a clear
pathological model of the disease and well-defined clinical
findings, IBS and PS symptoms are based on patients’ subjective
report of pain in the lower abdomen in the absence of organic
explanations for it. Despite these limitations, the results of this
joint andrological-gastroenterological study showed that the
simultaneous presence of PS and IBS is very common being
present in about one third of the patients evaluated and it had a
similar prevalence in patients seeking medical advice for PS or
IBS. This finding confirmed the epidemiological data showing a
prevalence of altered bowel habits in the 31.4% of 379 patients
with chronic prostatitis and the presence of prostate congestion
and swelling closely related to altered bowel habits in these
patients [29]. We observed that the gastrointestinal symptoms
and the severity score was similar in patients with PS plus IBS
versus patients with IBS alone. It is noteworthy that prostatitis
symptoms, such as total score and pain subscale, were more likely
to be diagnosed in patients with both diseases than in patients
with PS or IBS alone.
Our study design, applied to patients with prostatitis symptoms
and infertility, is corroborated by important results when the
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glass test [7], performed in all patients with PS plus IBS and in
those with PS alone, allowed to discriminate three main
conventional categories of prostatitis. The results showed that
patients with PS plus IBS had a higher prevalence of chronic
bacterial prostatitis and lower prevalence of non-inflammatory
prostatitis compared to patients with PS alone. The prevalence of
chronic bacterial prostatitis in this particular group of patients with
the simultaneous presence of PS and IBS resulted higher than the
low prevalence (5–10%) reported in other urological patient
population. The other two types of prostatitis identified (categories
IIIA and IIIB) had a similar prevalence: 60–65% for the category
IIIA and 30% for the category IIIB [9]. On the other hand, the
relative frequency of 14.1% in the PS group alone, apparently
higher than in other publications, is comparable with that reported
in our previous study showing that male accessory gland infections
(MAGI), abnormal semen quality, abnormal ultrasound and no
female infertility factor occurred in 122 out of 1187 (10.3%)
infertile couples evaluated during a 6-year period [30]. Using the
same criteria, this figure increased to 382 out of 2712 (13.8%)
infertile couples taking into account all the infertile couples who
came to our observation in the last 11 years.
Table 1. Demographic and symptoms of infertile patients with prostatitis syndromes (PS) and/or IBS and in a group of fertile men
(controls).
Characteristics PS plus IBS PS alone IBS alone Fertile men
Number of patients 111 106 139 25
Age (years) 3468.9 3369.2 3267.5 3266.3
Time since diagnosis (years) 461.3 361.4 361.6 NA
Prostatitis symptoms (NIH-CPSI score)
Total score 2464.5* 1863.8 1163.5 3.261.0
Pain subscale 14.961.8* 10.263.0 8.862.6 0.860.3
Urinary subscale 4.861.7 4.561.9 3.061.7 1.160.5
Quality-of-Life subscale 7.261.7 6.261.8 6.061.8 1.460.2
Gastrointestinal symptoms (frequency, %)
Abdominal pain/discomfort relieved by defecation 88.668.8{ 17.266.2 82.7610.7{ 1665.2
Change of bowel frequency 77.369.4{ 24.166.3 75.569.8{ 2067.5
Change of fecal consistency 80.768.5{ 25.866.6 76.268.9{ 2065.5
Constipation 51.168.6{ 17.263.4 51.1610.3{ 1662.7
Diarrhea 35.2610{ 8.664.8 41.062.2{ 0
Bloating 56.8611.5{ 12.164.1 56.161.3{ 861.0
Heartburn 50.0610.3{ 12.164.2 54.7611.8{ 861.0
IBS: irritable bowel syndrome; NA: not applicable.
Values are expressed as mean6SD.
*p,0.01 vs. the respective value observed in all the other groups of patients or in fertile men;
{p,0.01 vs. the respective value observed in the group with PS alone or fertile men.
doi:10.1371/journal.pone.0018647.t001
Table 2. Severity score of abdominal bowel habits in infertile patients with prostatitis syndromes (PS) and/or IBS and in a group of
fertile men (controls).
Symptoms score (mean, range) PS plus IBS PS alone IBS alone Fertile men
Number of patients 88 106 139 25
,3 bowel movements/week 1.661.14* 0.860.3 1.560.9* 0.660.1
.3 bowel movements/day 1.760.7* 0.760.2 2.061.2* 0.560.1
Hard or lumpy stools 1.861.1* 0.660.1 1.761.1* 0.460.1
Loose or watery stools 1.660.8* 0.660.2 1.661.2* 0.260.01
Defecation straining 2.260.4* 0.360.1 2.060.8* 0.260.01
Urgency 1.960.8* 0.760.3 1.860.9* 0.260.01
A feeling of incomplete bowel movement 2.461.5* 1.160.6 2.261.3* 0.560.1
Passing mucus 1.560.6* 0.760.1 1.460.8* 0.260.01
Abnormal fullness, bloating or swelling 3.061.5* 0.660.2 2.761.6* 0.460.2
IBS: irritable bowel syndrome.
Values are expressed as mean6SD;
*p,0.01 vs. the respective value observed in the group of patients with PS alone or in fertile men.
doi:10.1371/journal.pone.0018647.t002
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the broad range of prevalence (1.6–15%) [31,32] may be
explained by the lack of a deeper diagnostic approach to the
patient with not only PS but also infertility. The diagnosis PS
should be completed looking for a clinical presentation of MAGI
which more closely impair male fertility. Therefore, the wide
range of prostatitis may reflects various factors, such as: a) different
consulting physician speciality which has an impact on the work-
up of the patient; b) incomplete and not well defined diagnosis
(‘‘sperm infection’’ is an improperly used laboratory word and it
should be correctly replaced by the male diagnostic category
defined conventionally as MAGI); c) lack of clinical characteriza-
tion in patients initially fulfilling the conventional WHO criteria
(clinical history, physical signs, and prostatic fluid and ejaculate
signs). According to the hypothesis a), the elevated frequency of
CBP reported in the present study may also reflect the fact that a
large number of infertile patients, eventually to be submitted to
assisted reproductive techniques, are referred to our Andrology
Centre.
Finally, the higher prevalence of chronic bacterial prostatitis in
patients with PS plus IBS compared with that found in patients
with PS alone suggests to include ultrasound scans (didymo-
epididymal and prostate-vesicular) in the diagnostic work-out of
these patients to identify the possible presence of male accessory
gland infection (MAGI) [33,34] nested within this group. Indeed,
we have previously reported that patients with prostate-vesiculo-
epididymitis (PVE) have the worst sperm parameters and the
highest number of seminal leukocytes and radical oxygen species
production compared to patients with prostate-vesiculitus or
prostatitis alone [32,35] also in absence of important co-
morbidities, such as IBS.
Our findings suggest that patients with PS plus IBS may have
similar underlying pathophysiology, but they differ in severity. As
several studies suggested that the pathophysiological mechanism of
IBS are associated with specific symptom or subtype of prostatitis,
we speculate that the some mechanisms that underlies the
symptoms of IBS (such as an imbalance between commensal
and pathogen bacteria of the intestinal microflora; local low-grade
inflammation associated to IBS with abnormal immune function;
intestinal motility; and the intraluminal milieu) may play a role in
the pathophysiological mechanisms of both IBS and PS and
particularly in the onset of chronic bacterial prostatitis. Since only
10–56% of adults with symptoms of IBS seek medical evaluation
[36,37], a joint gastroenterological and andrological counseling for
men may represent a good opportunity in patients with PS. The
presence of more severe prostatitis symptoms (such as a higher
score at the pain subscale of the NIH-CPSI questionnaire) in
patients with double morbidity (PS plus IBS) suggests to extend the
application of the Rome III criteria to capture a possible presence
of IBS in these patients. In the same way, the presence and/or the
persistence of chronic bacterial prostatitis, even after the
administration of antimicrobials and/or antinflammatory drugs,
may suggest the presence of a conditioning co-morbidity such as
the IBS.
In conclusion, this study showed that prostatitis syndromes and
IBS are frequently associated in patients seeking medical advice for
prostatitis- or IBS-related symptoms. Furthermore, the presence of
IBS in patients with PS increases the prevalence of chronic
bacterial prostatitis and non-inflammatory prostatitis. On this
basis, we suggest that infertile patients with symptomatic PS should
undergo also be explored for the presence of IBS.
Materials and Methods
Case selection
Men who had been seen by andrologists or gastroenterologists
for symptoms that may be ascribed to PS or IBS, respectively. The
protocol was approved by the internal Institutional Review Board
and an informed written consent was obtained from each men.
Inclusion criteria. A patient was eligible for inclusion in this
study if all of the following criteria applied: a) patient aged .21
years; b) presence of primary infertility, defined as lack of
conception after at least 12 months of unprotected intercourse;
c) symptoms suggestive of PS with an NIH-Chronic Prostatitic
Symptom Index (NIH-CPSI) score .10; and d) diagnostic Rome
III criteria for IBS.
Exclusion criteria. A patient was not eligible for inclusion in
this trial if any the following criteria applied: a) history of disease
with possible adverse effects on infertility (varicocele,
cryptorchidism, sexual transmitted disease, testicular injury or
torsion, environmental and occupational gonadotoxic exposure);
b) presence of uni- or bilateral reduced testicular volume (,12 ml)
at the physical examination; c) medical treatments in the previous
3 months; and d) known female factor (ovarian, tubal, cervical) of
couple’s infertility.
Twenty-five fertile men (mean age 35 yrs, range 32–45 yrs) who
had fathered children within the previous 3 months and had
attended our Andrology Centre for previous fertility counseling
were also enrolled as controls. Fertile men were asked to complete
the Rome III for IBS and the NIH-CPSI questionnaires for
prostatitis.
Study design and survey methods
Identification of IBS associated with PS. A group of 152
patients consulting the Andrology outpatient clinic of the
University of Catania, mean age 33 years (range 26–45 years)
with the diagnosis of symptomatic PS (NIH-CPSI score .10) were
also asked to complete a Rome III questionnaire for IBS. Another
group of 204 consecutive patients, consulting the Gastroenterology
outpatient clinic of the University of Catania, mean age 34 years
(range 28–45 years), diagnosed with IBS according to the Rome
Table 3. Results from the Meares and Stamey test in infertile patients with prostatitis syndromes (PS) plus IBS or PS alone.
Findings in the expressed prostatic secretion







Microorganisms with or without leukocytes 30 (27.0%)* 15 (14.1%) Chronic bacterial prostatitis (type II)
Leukocytes without microorganisms 54 (48.7%) 57 (53.8%) Inflammatory prostatitis (Type IIIA)
No microorganisms and/or leukocytes in EPS 27 (24.3%)* 34 (32.1%) Non-inflammatory prostatitis (Type IIIB)
IBS: irritable bowel syndrome.
*p,0.01 vs. the respective value in patients with PS alone.
doi:10.1371/journal.pone.0018647.t003
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asked to fulfill the NIH-CPSI questionnaire for PS.
IBS patients were classified according to the frequency of nine
different abnormal bowel habits (,3 bowel movements/week; .3
movements/day; hard or lumpy stools; loose or watery stools;
straining during a bowel movements; urgency; feeling of incomplete
bowel movements; passing mucus during a bowel movement;
abdominal fullness, bloating or swelling) based on a 6-point scale (0,
none;1,,25%ofthetime;2,25–50%ofthe time;3,51–75%ofthe
time; 4, .75% of the time, but not always; 5, always).
The association of two or more of the following symptoms, with
recurrent abdominal pain or discomfort in at least 3 days/month
in last 3 months, were considered IBS (criteria fulfilled for the last
3 months with symptom onset at least 6 months prior to diagnosis):
1) improvement with defecation; 2) onset associated with a change
in frequency of stool; 3) onset associated with a change in form
(consistency) of stool.
At the beginning of the study, all patients were evaluated by the
same staff of andrologists, using a standardized history, physical
examination, and symptom score evaluation with the NIH-CPSI
questionnaire. Symptoms suggestive of PS included: pain or
discomfort, for at least 3 months in the previous 6 months, in the
pubic or bladder area, perineum, testicles, at the tip of the penis not
related to urination; ejaculatory pain, pain or burning during
urination, incomplete emptying, and urinary frequency. The NIH-
CPSI is a validated scale to measure these symptoms [5,6] which
commonly uses 13-item for the assessment of symptom severity in
men with PS, focusing on the three domains of: 1) painordiscomfort
(8 items); 2) urinary symptoms (2 items); and 3) quality-of-life (QOL)
impact (3 items). It has a total score range from 0 to 43, and includes
3 subscales addressing pain (score range 0–21), urinary symptoms
(score range 0–10), and QOL (score range 0–12). The pain subscale
consists of six items which are each scored from 0 to 1, one item
which is scored from 0 to 5, and one item which is scored from 0 to
10. The urinary subscale consists of two items, each of which is
scored from 0 to 3. The QoL subscale includes two items that are
scored from 0 to 3, and one item that is scored from 0 to 6. More
specifically, mild symptoms were defined by a pain score of 4–7 and
moderate or severe symptoms by a pain score of $8. Symptoms and
their effects were also grouped as mild, moderate and severe if CPSI
scores ranged from 0 to 14, 15 to 30 and 31 to 43, respectively. The
combined pain and urinary symptom score was then categorized
into mild (0 to 9), moderate (10 to 16) and severe (17 to 31).
Categorization of prostatitis syndromes (PS). Since the
symptoms of chronic bacterial prostatitis (category II) cannot be
distinguished from those of CP/CPPS (category IIIA and IIIB),
following an initial screening, all patients with suspected PS (NIH-
CPSI score .10) and IBS, underwent to the four glass test
proposed by Meares and Stamey [7]. It requires that the following
specimens will be obtained for microscopy and culture: the first
voided 5–10 ml urine (VB1), midstream urine (VB2), pure
prostatic secretion expressed by prostatic massage (EPS) and the
first voided 5–10 ml urine after prostatic massage (VB3). The
findings of microorganism(s) with or without leukocytes, leukocytes
without microorganisms or no leukocytes and no microorganisms
in EPS and/or VB3 suggests that diagnosis of chronic bacterial,
inflammatory and non-inflammatory prostatitis, respectively [8].
The diagnosis of chronic prostatitis NIH type II was made
clinically and based on microbiological tests following the
consensus criteria of the NIH [8].
For the Meares and Stamey test, we considered the test positive
if there was a 10-fold increase in bacteria in the EPS or in the VB3
samples compared with the VB1 and VB2 specimens. All the
samples of this study were centrifuged and seeded on blood agar
and McConkey media with standard biochemical tests to
characterize bacteria. Microbiological evaluation included micro-
scopic evaluation of VB1 with cytological analysis for leukocytes
[38], quantitative culture methods for relevant pathogen bacteria
(including Enterobacteriaceae, mycoplasmas, C. trachomatis and
Candida spp.) in urethral discharge smears and in VB1 and either:
C. trachomatis positive in VB1 and/or urethral smears, or
presence of common bacteria, mycoplasmas, or yeasts with a
concentration $10
4 CFU/ml in the urethral discharge and/or
$10
3 CFU/ml in VB1, were considered criteria for diagnosis
[38]. Additionally, inflammatory WBCs were counted on four-
glass specimens and semen using the more stringent composite
criteria (10+ in EPS, 5+ in VB3) described by Schaeffer and
colleagues [39].
Statistical Analysis
Results are shown as mean6SD throughout the text unless
otherwise indicated. The Student’s t test was used to compare the
distribution of demographic, symptomatic and sperm variables.
The frequency of clinical and microbiological findings between
groups were analyzed by the chi-square test or Fisher’s exact test,
as appropriate. The sub-analysis of semen variables, because of the
non-Gaussian distribution of the semen variables studied, were
expressed as median and 10
th and 90
th percentiles and processed
using non parametric tests (Mann-Whitney test). The software
SPSS 9.0 for Windows was used for statistical evaluation. A
statistically significant difference was accepted when the p value
was lower than 0.05.
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